Earlier this week I pondered which four ASX stocks I would purchase under a 'buy-and-hold' strategy if I just happened to be the lucky recipient of a $10,000 windfall – you can see my picks here.
Suppose for a second that I'm having a really lucky week and I've just happened across another $10,000 to invest in the market!
As you may have guessed by the title, I'm going to be a 'little' (actually a lot!) more bullish with this next $10,000. While I'm not exactly taking the cash down to the casino to gamble it all on red, it must be said that I am taking significantly high-stakes bets with this $10,000 by buying some fast growing but very highly priced stocks – much higher that what I'm generally comfortable paying.
iProperty Group Ltd (ASX: IPP) has already rallied over 200% in the past year and now boasts a market capitalisation of $550 million. The Asia-focussed online property portal recently reported "strong organic growth" with cash receipts increasing 26% in the first half to $11.3 million. It's a hefty multiple of revenues to pay for the business, but the potential for iProperty to become the equivalent of REA Group Limited (ASX: REA) in Asia is enticing to say the least!
iCar Asia Ltd (ASX: ICQ) is to automotive advertising what iProperty is to real estate. Once again the idea that iCar Asia could corner the classifieds markets in Malaysia, Indonesia and Thailand in the same way Carsales.Com Ltd (ASX: CRZ) has in Australia is seriously appealing. iCar Asia is not for the faint hearted either, with a market capitalisation of $300 million and cash receipts of just $670,000 in the March quarter, this stock is also richly priced.
MOBEMBRACE FPO (ASX: MBE) provides shareholders with exposure to the super-fast growing mobile advertising and mobile payments space. As more and more consumers around the world upgrade to mobile devices, advertisers are increasingly looking for ways to utilise this new media and that's where Mobile Embrace comes in. Even capturing a small share of this global market could richly reward shareholders.
Starpharma Holdings Limited (ASX: SPL) is a biotech with a market capitalisation of $170 million. The share price is currently trading at 60 cents which is near a multi-year low. As recently as November 2012 the stock was trading above $1.50. Unlike many biotech stocks which only have products in development, Starpharma actually has products which are on sale and already providing revenues to the group along with other products which are very close to commercial start. Starpharma's suite of diversified products is appealing and the later stages of development decrease (to a degree) the risks.
